• Frontline
  • Warren Buffett
  • Volvo
  • NASDAQ Composite Index
  • 10 Year Treasury
  • Commercial Banks
  • JPMorgan Chase
  • Emerging Markets
  • Commerce Department
  • Home
  • Practice Management
  • Research & Insights
  • Alternatives
  • ETF Managed Portfolios
  • Home>Biosimilars in Emerging Markets 2017: Focus on Brazil, Russia, India, China, Mexico and South Korea - Research and Markets

    Biosimilars in Emerging Markets 2017: Focus on Brazil, Russia, India, China, Mexico and South Korea - Research and Markets

    Biosimilars in Emerging Markets 2017: Focus on Brazil, Russia, India, China, Mexico and South Korea - Research and Markets

    11/09/2017

    Biosimilars in Emerging Markets 2017: Focus on Brazil, Russia, India, China, Mexico and South Korea - Research and Markets

    The "Biosimilars in Emerging Markets" report has been added to Research and Markets' offering.

    Follow-on biologics have been embraced enthusiastically in most emerging markets, where they promise to deliver much-needed improvements in access to a generation of products that remains beyond the reach of many patients. They have been registered in substantial numbers, and have been prescribed and purchased widely, expanding treatment populations and eroding originator revenues.

    By the early part of this decade, follow-on biologics were generating annual sales of around $600m in China alone. With follow-on products winning key government tenders in countries like Mexico and Russia, and being purchased by a growing number of patients in self-pay markets such as India, aggregate sales of copy biologics in the six BRIC-MS (Brazil, Russia, India, China, Mexico, and South Korea) countries now almost certainly exceed $1.5bn.

    Many follow-on biologics being sold in BRIC-MS countries were subject to cursory regulatory reviews, and would not meet biosimilarity standards required to obtain marketing authorization in highly regulated markets. Some have been tested more rigorously, however, and manufacturers based in South Korea and India have begun to emerge as major players on the global biosimilars stage.

    Key Topics Covered:

    1 EXECUTIVE SUMMARY

    • Low IP and regulatory barriers provided an early path to market
    • Original biologics have been hit hard in BRIC-MS markets
    • Tighter regulations have begun to affect BRIC-MS market dynamics
    • Governments remain firmly on the side of local manufacturers
    • Leading BRIC-MS players are spreading their wings
    • The long-term potential of BRIC-MS biosimilar markets is huge

    2 THE BIOSIMILARS MARKET